Functional analysis of a putative ATM/ATR substrate RFWD3
假定的 ATM/ATR 基板 RFWD3 的功能分析
基本信息
- 批准号:7893391
- 负责人:
- 金额:$ 11.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-31 至 2010-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAntibodiesApoptosisAtaxia-Telangiectasia-Mutated protein kinaseBRCA1 geneBindingBiochemicalCell CycleCell Cycle ArrestCell physiologyCellsComplexDNA DamageDNA damage checkpointDefectGenetic TranscriptionGenome StabilityGenotoxic StressHumanIn VitroKnowledgeLigaseMDM2 geneMalignant NeoplasmsMapsMass Spectrum AnalysisMediatingMolecularMutationPathway interactionsPeptide HydrolasesPhosphorylationPhosphorylation SitePlayPolyubiquitinProtein p53ProteinsProteomicsRing Finger DomainRoleSignal PathwaySignal Transduction PathwaySmall Interfering RNASystemTP53 geneTestingTumor Suppressor ProteinsUbiquitinUbiquitinationUp-RegulationWD Repeatcross reactivityin vivomulticatalytic endopeptidase complexnoveloncoprotein p21preventprogramsresponsetherapy developmentubiquitin ligaseubiquitin-protein ligaseubiquitin-specific protease
项目摘要
Project Description
The tumor suppressor protein p53 is a key regulator of cell cycle arrest, apoptosis and genomic stability.
Mutations of p53 that compromise its function occur in 50% of human cancers. In unstressed cells, p53 is
maintained at low levels; this is achieved by the ubiquitin-proteasome system, in which p53 is ubiquitinated by
E3 ligases and targeted for degradation. In response to genotoxic stress, p53 needs to be rapidly stabilized to
upregulate gene transcription. At least five ubiquitin ligases (E6-AP, HDM2, ARF-BP1, COP1, and PIRH2) and
an ubiquitin-specific protease (HAUSP) that opposes the ligases have been identified to mediate ubiquitin-
dependent proteasomal degradation of p53. However, how these ligases and protease coordinate to regulate
p53 stability, particularly after DNA damage is not clear. DNA damage checkpoints are signal transduction
pathways that stop or delay the cell cycle progress in the presence of DNA damage. Two kinases, ATM and
ATR, are key upstream regulators of this pathway. In a proteomic screen for novel substrates for our
preliminary studies, we found that ring finger and WD repeat domain 3 (RFWD3) protein is a putative
ATM/ATR substrate that is required for cell cycle arrest. Furthermore, we found that RFWD3 is required for
stabilization of p53 in response to DNA damage. We hypothesize that RFWD3 is a novel E3 ligase that plays
an important role in mammalian DNA damage response network in part by serving as a positive regulator of
p53 stability. We propose to 1) determine the mechanism by which RFWD3 regulates DNA damage
checkpoint; whether this is achieved by modulating p53 ubiquitination and stability; 2) to map the RFWD3
phosphorylation sites and test how its phosphorylation by ATM/ATR regulates its function; 3) to isolate
RFWD3-associated complexes in cycling cells and in response to DNA damage and identify their components
by mass spectrometry; we aim to find and validate important RFWD3 regulators and its E3 ligase substrates,
thus revealing clues for its other cellular functions. Project Narrative
RFWD3 is a newly identified putative ATM/ATR substrate that, when inactivated by siRNA, causes defects in
p53 accumulation and cell cycle arrest. Thus, RFWD3 may play an important role in the mammalian DNA
damage response network by serving as a novel E3 ligase that positively regulates p53 stability. Uncovering
new positive regulator of p53 and understand its function will potentially advance our knowledge of cancer
development and treatment.
项目说明
抑癌蛋白P53是细胞周期停滞、细胞凋亡和基因组稳定的关键调节因子。
破坏其功能的p53突变发生在50%的人类癌症中。在非应激细胞中,P53是
维持在低水平;这是通过泛素-蛋白酶体系统实现的,在该系统中,p53被泛素化
E3连接酶和靶向降解。为了应对基因毒性应激,P53需要迅速稳定到
上调基因转录。至少五种泛素连接酶(E6-AP、Hdm2、ARF-BP1、COP1和PIRH2)和
一种与连接酶相反的泛素特异蛋白酶(Hausp)已被确定为介导泛素-
依赖蛋白酶体对P53的降解。然而,这些连接酶和蛋白酶是如何协同调节的
P53的稳定性,特别是DNA损伤后的稳定性尚不清楚。DNA损伤检查点是信号转导
在存在DNA损伤的情况下,停止或延缓细胞周期进展的途径。两个激活器,自动柜员机和
ATR是这一途径的关键上游调节因子。在蛋白质组筛选中寻找我们的新底物
初步研究发现,无名指和WD重复结构域3(RFWD3)蛋白是一种可能的
细胞周期停滞所需的ATM/ATR基板。此外,我们发现RFWD3是必需的
DNA损伤对P53的稳定作用。我们假设RFWD3是一种新的E3连接酶,
在哺乳动物DNA损伤反应网络中发挥重要作用,部分原因是作为一种正向调节因子
P53的稳定性。我们建议1)确定RFWD3调节DNA损伤的机制
检查点;这是否通过调节p53泛素化和稳定性来实现;2)定位RFWD3
并检测ATM/ATR对其功能的调节作用;3)分离
循环细胞中与RFWD3相关的复合体及其对DNA损伤的反应及其成分鉴定
我们的目标是寻找和验证重要的RFWD3调节子及其E3连接酶底物,
从而揭示了它的其他细胞功能的线索。项目叙事
RFWD3是一种新发现的ATM/ATR底物,当被siRNA灭活时,会导致
P53积聚和细胞周期停滞。因此,RFWD3可能在哺乳动物DNA中发挥重要作用
作为一种新的E3连接酶,积极调节P53的稳定性,从而破坏反应网络。揭开面纱
新的P53正向调节因子和对其功能的了解可能会促进我们对癌症的认识
发展和治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YI WANG其他文献
YI WANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YI WANG', 18)}}的其他基金
Functional analysis of a putative ATM/ATR substrate RFWD3
假定的 ATM/ATR 基板 RFWD3 的功能分析
- 批准号:
7460173 - 财政年份:2008
- 资助金额:
$ 11.51万 - 项目类别:
Functional analysis of a putative ATM/ATR substrate RFWD3
假定的 ATM/ATR 基板 RFWD3 的功能分析
- 批准号:
7666860 - 财政年份:2008
- 资助金额:
$ 11.51万 - 项目类别:
Functional analysis of a putative ATM/ATR substrate RFWD3
假定的 ATM/ATR 基板 RFWD3 的功能分析
- 批准号:
8306357 - 财政年份:2008
- 资助金额:
$ 11.51万 - 项目类别:
Functional analysis of a putative ATM/ATR substrate RFWD3
假定的 ATM/ATR 基板 RFWD3 的功能分析
- 批准号:
7892934 - 财政年份:2008
- 资助金额:
$ 11.51万 - 项目类别:
Functional analysis of a putative ATM/ATR substrate RFWD3
假定的 ATM/ATR 基板 RFWD3 的功能分析
- 批准号:
8136628 - 财政年份:2008
- 资助金额:
$ 11.51万 - 项目类别:
STRUCTURE STUDY OF HUMAN NMT BY XRAY CRYSTALLOGRAPHY
X射线晶体学对人体NMT结构的研究
- 批准号:
6483459 - 财政年份:2001
- 资助金额:
$ 11.51万 - 项目类别:
STRUCTURE STUDY OF HUMAN NMT BY XRAY CRYSTALLOGRAPHY
X射线晶体学对人体NMT结构的研究
- 批准号:
6339283 - 财政年份:2000
- 资助金额:
$ 11.51万 - 项目类别:
STRUCTURE STUDY OF HUMAN NMT BY XRAY CRYSTALLOGRAPHY
X射线晶体学对人体NMT结构的研究
- 批准号:
6315663 - 财政年份:1999
- 资助金额:
$ 11.51万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 11.51万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 11.51万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 11.51万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 11.51万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 11.51万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 11.51万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 11.51万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 11.51万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 11.51万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 11.51万 - 项目类别: